RGNX logo

REGENXBIO Inc.

RGNX

RGNX: Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).

more

Show RGNX Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of RGNX by members of U.S. Congress

Politician Type Traded
Peter Welch House / D Sale $1,001 - $15,000 Nov. 08, 2019
Peter Welch House / D Purchase $1,001 - $15,000 Oct. 22, 2019
Whale Activity

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard
Insider Trading

Quarterly net insider trading by RGNX's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $90,000 Jul 19, 2023 Issue: Taxation/Internal Revenue Code Immigration Copyright/Patent/Trademark Trade (domestic/foreign) Health Issues
  • $163,000 Apr 19, 2023 Issue: Taxation/Internal Revenue Code Immigration Copyright/Patent/Trademark Trade (domestic/foreign) Health Issues
  • $70,000 Jan 18, 2023 Issue: Taxation/Internal Revenue Code Immigration Copyright/Patent/Trademark Trade (domestic/foreign) Health Issues
  • $70,000 Oct 15, 2022 Issue: Taxation/Internal Revenue Code Immigration Copyright/Patent/Trademark Trade (domestic/foreign) Health Issues
  • $82,000 Jul 20, 2022 Issue: Taxation/Internal Revenue Code Immigration Copyright/Patent/Trademark Trade (domestic/foreign) Health Issues
  • $150,000 Apr 20, 2022 Issue: Taxation/Internal Revenue Code Immigration Copyright/Patent/Trademark Trade (domestic/foreign) Health Issues
  • $60,000 Jan 17, 2022 Issue: None
  • $75,000 Dec 14, 2021 Issue: None
  • $40,000 Jul 20, 2021 Issue: None
  • $60,000 Apr 21, 2021 Issue: None
  • $60,000 Jan 21, 2021 Issue: None
  • $60,000 Oct 20, 2020 Issue: None
  • $185,000 Jul 20, 2020 Issue: None
  • $110,000 Apr 20, 2020 Issue: None
  • $50,000 Jan 31, 2020 Issue: None
  • $50,000 Oct 21, 2019 Issue: Immigration Health Issues Copyright/Patent/Trademark Trade (domestic/foreign)
  • $130,000 Aug 06, 2019 Issue: Health Issues Trade (domestic/foreign) Copyright/Patent/Trademark
  • $50,000 Apr 19, 2019 Issue: Health Issues Copyright/Patent/Trademark Trade (domestic/foreign)
U.S. Patents

New patents grants

  • Patent Title: Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) produced by human neural or glial cells Mar. 28, 2023
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of RGNX in WallStreetBets Daily Discussion

RGNX News

Recent insights relating to RGNX

CNBC Recommendations

Recent picks made for RGNX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in RGNX

Corporate Flights

Flights by private jets registered to RGNX